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CORRELACIÓN ENTRE LOS PRODUCTOS
DE OXIDACIÓN DE COLESTEROL (COPs)
FORMADOS POR AUTOOXIDACIÓN
Y FACTORES DE RIESGO CARDIOVASCULAR 
Resumen
Introducción: Se ha demostrado que los factores de
riesgo cardiovascular están estrechamente asociados con
un elevado nivel de estrés oxidativo. Varios estudios con-
sideran a los productos de oxidación del colesterol
(COPs) como marcadores específicos in vivo de estrés
oxidativo. El objetivo de este trabajo fue estudiar la aso-
ciación entre los niveles de COPs derivados de procesos
de autooxidación de colesterol y factores de riesgo cardio-
vascular, comparando el contenido sérico de COPs en
sujetos afectados o no por dichos factores.
Métodos: Se trata de un estudio transversal en el que se
reclutaron 88 personas a las que se analizó el perfil de óxi-
dos de colesterol en suero procedentes de autooxidación,
por cromatografía de gases-espectrometría de masas. Se
valoró la correlación de los niveles de COPs con difer-
entes factores de riesgo cardiovascular. 
Resultados y discusión: Se encontró una gran variabili-
dad en el contenido en COPs totales, observándose val-
ores entre 0,091 y 2,052 μg/mL. COPs totales fueron sig-
nificativamente superiores (p < 0,05) en pacientes con
hipertrigliceridemia, hipertensión, diabetes y sobrepeso/
obesidad con respecto a aquellos sujetos que no presen-
taron estos factores de riesgo cardiovascular. Además, 7α
y 7β-hidroxicolesterol y 7-ketocolesterol mostraron val-
ores mayores (p < 0,05) en pacientes con hipertensión y
diabetes. No se observaron diferencias en COPs totales
entre pacientes con y sin hipercolesterolemia. 
Conclusiones: Los resultados de este estudio mostraron
que los COPs analizados presentan altos niveles de cor-
relación con, al menos, 4 de 6 factores de riesgo cardiovas-
cular considerados.
(Nutr Hosp. 2011;26:144-151)
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Abstract
Background/aims: Risk factors for cardiovascular dis-
ease (CVD) have been proven to be associated with an
increased oxidative stress. Several studies have consid-
ered cholesterol oxidation products (COPs) as specific in
vivo markers of oxidative stress. The aim of this study was
to investigate the association between the levels of COPs
derived from autoxidation processes and established car-
diovascular risk factors, comparing the levels of serum
COPs in subjects with or without showing values out of
the reference ranges. 
Methods: It was a cross-sectional study in which 88
subjects were recruited and individual and total COPs
from autoxidation origin was analyzed in serum by GC-
MS. The simultaneous correlation of COPs with different
CVD risk factors have been analyzed.
Results and discussion: A great variability of total
COPs concentrations were found. Subjects presented
total COPs values from 0.091 to 2.052 μg/mL. Total COPs
were significantly higher (p < 0.05) in patients with hyper-
triglycerolemia, hypertension, diabetes and overweight/
obesity status compared to those subjects who did not
present those CVD risk factors. Moreover, 7α and 7β-
hydroxycholesterol and 7-ketocholesterol were signifi-
cantly higher (p < 0.05) in patients with hypertension and
diabetes. No significant differences in total COPs were
found between patients with and without hypercholes-
terolemia.
Conclusions: The obtained results showed that the
analyzed COPs correlate well with at least 4 out of 6 risk
factors of development of CVD.
(Nutr Hosp. 2011;26:144-151)
DOI:10.3305/nh.2011.26.1.4690
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Introduction
Cholesterol is an unsaponificable lipid prone to oxida-
tion leading to the formation of cholesterol oxidation
products (COPs). Certain oxysterols of biomedicalinter-
est (e.g., 26-OH-cholesterol, 24-OH-cholesterol, and
22-OH-cholesterol) are generallyconsidered to not rep-
resent significant products of the autoxidationof choles-
terol, while others (including 7-ketocholesterol, 7β-OH-
cholesterol, 7α-OH-cholesterol, 25-OH-cholesterol,
5β,6β-epoxycholesterol, 5α,6α-epoxycholesterol, and
5α,6β-diOH-cholesterol) are recognized products of
cholesterol autoxidation.1 These last ones could be both
from endogenous origin or also they can be absorbed
from the diet.2,3
The presence of COPs in plasma or serum has been
evident, and it has been demonstrated that they are
potentially involved in the initiation and progression of
major chronic diseases.4 They are present in high con-
centrations in atherosclerotic plaques, contributing to
the development of atherosclerosis, the most common
cause of death in Western world.5
Chronic and acute over-production of reactive oxy-
gen species (ROS) under pathophysiologic conditions
are associated with the development of CDV.6 There is
growing evidence that oxidized LDL (oxLDL) plays a
major role in the injury of endothelium, being its con-
tent in COPs the reactive mediator of structural and
functional changes of the vascular entothelium
affected by atherosclerotic process.7,8 oxLDL is not rec-
ognized by LDL receptors, but it is instead taken up by
scavenger receptors on macrophagues of arterial walls.
The macrophagues then develop into foam cells that
form a fatty streak that ultimately turn into an athero-
sclerotic plaque.9
Zhou et al.10 found that plasma from catheterized
patients showed much higher total free oxysterols than
control ones, being the most abundant those from
autoxidation origin. Larsson et al.11 showed that
increased levels of 7β-hydroxycholesterol and 7-ketoc-
holesterol may play an important role in the induction
of oxidative stress in atheroma plaques by stimulating
ROS production and decreasing cellular antioxidants. 
Several diseases are associated with local substained
imbalance of the ratio between oxidative and reductive
biochemical reactions towards oxidation, causing
oxidative stress. Increased COPs levels (specially 7-
ketocholesterol and 7β-hydroxycholesterol) have been
reported in disease states where oxidative stress was
increased such as diabetes mellitus12 or familial com-
bined hyperlipidemia.13. For instance, functional
impairment of the vascular endothelium is one of the
first steps in the development of atherosclerosis, and
vascular adhesion molecules in plasma are indicators
of endothelial damage in diabetes mellitus showing
significant correlation with 7-ketocholesterol.14 Signif-
icantly higher concentrations of blood COPs were
found in the blood of diabetic and hypercholes-
terolemic patients than in blood of control subjects.15
Other authors cannot exclude the role of COPs (7-
oxysterols) in pathogenesis of arterial hypertension
and non-insulin dependent diabetes mellitus in morbid-
ity obese patients.16 Obesity is linked with enhanced
inflamatory stress and increased atherosclerosis, which
are associated with oxidative stress and greater forma-
tion of COPs. A recent study has established that serum
oxysterol concentrations in adolescents increase with
obesity, insulin, and ApoB indicating its relevance as
potential indicators for assessing certain metabolic
derangements.17
The ultimate goal of research on COPs should be to
link findings regarding the biological roles of COPs to
the prevalence of COPs in tissues or fluids, contribut-
ing with interesting data on the “focused” lipidomics
research area.18 In this context, the aim of this study was
to investigate the association between the levels of
COPs derived from autoxidation processes and estab-
lished cardiovascular risk factors,19 comparing the lev-
els of serum COPs in subjects with or without showing
values out of the reference ranges. 
Materials and Methods
Materials and reagents
7α-Hydroxycholesterol, 7β-hydroxycholesterol, 5,6β-
epoxycholesterol, 5,6α-epoxycholesterol, cholestanetriol,
25-hydroxycholesterol, 7-ketocholesterol and 19-
hydroxycholesterol were purchased from Steraloids
(Wilton, NH, U.S.A.). Tri-Sil reagent was obtained
from Pierce (Rockford, IL, U.S.A.). Acetone, chloro-
form, diethyl ether, methanol, hexane, sodium sulphate
anhydrous and potassium hydroxide were obtained
from Panreac (Barcelona, Spain). Hexane for gas chro-
matography and butylhydroxytoluene (BHT) were
from Merck & Co., Inc (Whitehouse Station, NJ,
U.S.A.). Sep-pack Vac 6cc silica 1g cartridges were
obtained from Waters (Milford, Massachussets,
U.S.A.).
Study population
This cross sectional study was performed in 88 sub-
jects (55.7 % males; 63.5 ± 14.7 yr) attending the Car-
diovascular Risk Area of the University of Navarra for
a general check-up. 
All participants underwent a complete medical
examination and anthropometric measurements were
taken. Subjects were free from clinically apparent ath-
erosclerotic disease on the basis of absence of history
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of coronary disease, stroke, or peripheral artery disease
and normal electrocardiogram. Exclusion criteria
were: impaired renal or liver function, cancer, arteritis,
inflammatory diseases and connective tissue diseases.
The mean body mass index (BMI) was 28.8 kg/m2, and
it was calculated using the following formula: weight
(kg)/height2 (m). Blood pressure was measured on the
right arm, with the subjects in a seated position and
after a 5-min rest, with a mercury sphygmomanometer.
The average of two measurements, at the beginning
and end of the visit, was considered.
Risk factors for CVD were diagnosed according to
the National Cholesterol Education Program’s Adult
Treatment Panel III guidelines with modification of
waist criterion into body mass index (BMI).
The local committee on human research approved
the study, performed in accordance with the Declara-
tion of Helsinki, and all participants gave written
informed consent.
Biochemical analysis
Following an overnight fast, serum and plasma were
collected by venous puncture into Vacutainer tubes.
Fasting serum glucose, cholesterol, triglycerides (TG),
and high-density lipoprotein (HDL) and low-density
lipoprotein (LDL) cholesterol were measured by stan-
dard laboratory techniques. 
Serum COPs analysis
A validated method for the analysis of COPs in
serum was used, by means of GC-MS Menéndez-Car-
reño et al.20 Gas chromatography-Mass spectrometry
analysis was performed on a GC 6890N Hewlett
Packard coupled to a 5975 Mass Selective Detector
(Agilent Technologies, Inc., CA, USA). The TMS-
ethers derivates of sterol oxides were separated on a
capillary column Varian VF-5ms CP8947 (50 m x 250
m x 0.25 m film thickness) (Varian, France). Identifi-
cation of the peaks was made by the characteristic ion
fragmentation of the standard substances and the quan-
tification was made using selected ion monitoring
(SIM) analysis. Integration was performed with Agi-
lent G1701DA GC/MSD ChemStation (Agilent Tech-
nologies, Inc., CA, U.S.A.).
Seven different cholesterol oxidation products were
analyzed as it has been demonstrated that 7α-hydroxy-
cholesterol, 7β-hydroxycholesterol, 5,6α-epoxide,
5,6β-epoxide, triol, 25-hydroxycholesterol and 7-keto-
cholesterol are the most predominant COPs derived
from autooxidation in vivo.21
Statistical analysis
The statistical analysis was performed with ver-
sion 15.0; SPSS (Chicago, IL). The normal distribu-
tion of variables was tested with the Shapiro Wilks
test. Differences between groups were evaluated
with the Student t test and with the Mann-Whitney U
test for non-normally distributed variables. Spear-
man correlation coefficients for continuous variables
were used to assess univariate correlations. Results
are presented as mean ± EEM, p < 0.05 was consid-
ered significant.
Results 
Regarding demographic and clinical characteristics of
the study population, the most prevalent risk factor was
dislipemia (79.4%) (data not shown). Mean cholesterol
was 200 ± 49 mg/dL (HDL = 56 ± 15 mg/dL, LDL = 124
± 47 mg/dL and VLDL = 21 ± 9 mg/dL) and 47% of the
study participants were normocholesterolemic. There
were 37.5% of hypertensive patients, most of them (30.7
% of the volunteers) under treatment with antagonists of
the angiotensin II receptor or ACE inhibitors. Mean SBP
was 136 ± 20 mmHg and mean DBP was 77 ± 11
mmHg. The prevalence of diabetes was 18.6%. 47.7%
of the participants were smokers. 
The minimum and maximum concentrations of total
and individual serum COPs observed are shown in
table I. Total analyzed COPs results ranged from 0.091
to 2.053 μg/mL. Various authors have reported total
plasma/serum COPs values in normal volunteers rang-
ing from 0.02 μg/mL to 9.6 μg/mL.2,22,23 The main cho-
lesterol oxidation products found in serum were 7α-
hydroxycholesterol and 7β-hydroxycholesterol (0.304
and 0.247 μg/mL, respectively), followed by 7-ketoc-
holesterol and 5,6β-epoxycholesterol (0.062 and 0.060
μg/mL, respectively). No 25-hydroxycholesterol was
detected in serum samples.
Table I
Serum concentration of individual COPs [μg/mL] (n = 88)
COPs (μg/mL) 7α-hydroxy 7β-hydroxy 5,6β-epoxy- 5,6α-epoxy- Cholestanetriol 25-hydroxy- 7-keto-
cholesterol cholesterol cholesterol cholesterol cholesterol cholesterol
Minimum concentration 0.011 0.016 0.002 0.003 0.003 n.d. 0.006
Maximum concentration 1.092 0.762 0.241 0.264 0.162 n.d. 0.242
Mean 0.304 0.247 0.06 0.046 0.034 n.d. 0.062
n.d.: non detectable.
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Subjects were classified into two groups depending
on the presence or absence of different CVD risk fac-
tors, following the criteria described by the ATP III
guidelines.19 Hypercholesterolemia was defined as
cholesterol levels higher than 240 mg/dL. Low HDL
was characterized as HDL levels lower than 40 mg/dL
for women and lower than 50 mg/dL for men. Hyper-
triglyceridemia was considered when triglycerides lev-
els were higher than 150 mg/dL. In relation to hyper-
tension, the Sixth Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure defined categorical
hypertension as a blood pressure ≥ 140 mm Hg systolic
or ≥ 90 mm Hg diastolic.24 Diabetes was described as
fasting blood glucose levels higher than 126 mg/dL.25
Finally, overweight and obesity were classified accord-
ing to body mass index (BMI) criteria described by the
National Institutes of Health (BMI > 25 kg/m2 for over-
weight and > 30 kg/m2 for obesity.26
Regarding hypercholesterolemia, there were no sig-
nificant differences between the two groups of sub-
jects, with and without hypercholesterolemia, for total
COPs levels, 7-ketocholesterol being the only oxide
that showed some trend to signification (p = 0.08)
(table II). In relation to HDL levels, total COPs concen-
trations were higher in patients with low HDL levels
(0.91 μg/mL) than in subjects with high HDL levels
(0.70 μg/mL),but no statistical significance was
noticed (table II). 
Subjects with hypertriglyceridemia showed signifi-
cantly higher total COPs levels (1.02 μg/mL) than
those without hypertriglyceridemia (0.71 μg/mL)
(table II). These differences were due to 7α-hydroxyc-
holesterol, which showed significant differences
between both groups, and also to the quantitatively
great differences (although not statistically significant
p = 0.08) found for 7β-hydroxycholesterol.
Results regarding COPs concentrations depending on
the blood pressure of subjects are shown in table III.
There were significant differences between the two
groups for total COPs levels (0.89 μg/mL for hyperten-
sive patients and 0.61 μg/mL for normal subjects),
detecting significant increased levels of cholesterol
oxides at C7 position. The rest of the COPs, 5,6β-epoxy-
cholesterol, 5,6α-epoxycholesterol and cholestanetriol
did not show significant differences between both
groups. Similar results were found when COPs were
analyzed in subjects with and without diabetes (table
III). 7α-hydroxycholesterol, 7β-hydroxycholesterol
and 7-ketocholesterol showed significant increases in
subjects with diabetes in relation to subjects which did
not suffer from this disease. Total COPs were also sig-
nificantly higher in those patients (1.00 and 0.70 μg/mL,
respectively).
In relation to subjects which were classified
according to their BMI, significant differences were
found between subjects with BMI higher or lower
than 30 kg/m2, showing 1.05 μg/mL in the first case
and 0.71 μg/mL in the latest. In obese population, 7α-
hydroxycholesterol and 7β-hydroxycholesterol also
showed a trend to signification, with p values of 0.07
and 0.08, respectively (table IV). An evaluation of the
COPs content in overweight + obesity subjects was
also done. In this case, significantly higher values
were found for total COPs in the group with a BMI >
25 kg/m2, with 0.84 μg/mL, compared to 0.60 μg/mL
that was observed for the group with BMI < 24.9
kg/m2. 7α-hydroxycholesterol was the only COP that
presented significant differences between these two
groups.
Table II
Serum COPs concentrations [μg/mL] according to total lipids levels
CVD risk factor
COPs (μg/mL)
Total COPs 7α-hydroxy 7β-hydroxy 5,6β-epoxy- 5,6α-epoxy- Cholestanetriol 7-keto-
cholesterol cholesterol cholesterol cholesterol cholesterol
Total cholesterol
< 240 mg/dL (n = 56) 0.70 ± 0.50 0.29 ± 0.27 0.22 ± 0.19 0.06 ± 0.05 0.04 ± 0.03 0.03 ± 0.03 0.06 ± 0.05
> 240 mg/dL (n = 29) 0.86 ± 0.57 0.32 ± 0.32 0.30 ± 0.21 0.07 ± 0.05 0.05 ± 0.05 0.04 ± 0.03 0.08 ± 0.06
p n.s. n.s. n.s. n.s. n.s. n.s. p = 0.08
Low HDL
HDL > 40 mg/dL (women);
HDL >  50 mg/dL (men) (n = 63) 0.70 ± 0.49 0.27 ± 0.25 0.23 ± 0.20 0.06 ± 0.05 0.05± 0.04 0.03 ± 0.03 0.06 ± 0.06
HDL < 40 mg/dL (women);
HDL < 50 mg/dL (men) (n = 22) 0.91 ± 0.61 0.41 ± 0.36 0.29 ± 0.21 0.06 ± 0.04 0.04 ± 0.03 0.04 ± 0.03 0.06 ± 0.04
p n.s. n.s. n.s. n.s. n.s. n.s. n.s.
Total triglycerides
< 150 mg/dL (n = 71) 0.71 ± 0.50 0.28 ± 0.28 0.23 ± 0.19 0.06 ± 0.05 0.04 ± 0.04 0.03 ± 0.03 0.06 ± 0.05
> 150 mg/dL (n = 11) 1.02 ± 0.71 0.44 ± 0.37 0.37 ± 0.26 0.06 ± 0.05 0.04 ± 0.03 0.03 ± 0.03 0.07 ± 0.05
p * p = 0.08 * n.s. n.s. n.s. n.s
Results are expressed as mean ± standard deviations. * p < 0.05; n.s.: non significant.
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Figure 1 shows COPs concentrations in relation to the
different CVD risk factors evaluated in this work.
Analysis of COPs concentrations revealed a significant
increase in total COPs levels in patients presenting
hypertriglycerolemia, hypertension, diabetes and over-
weight/obesity status. Regarding hypercholesterolemia
and HDL levels, COPs did not show significant differ-
ences with the presence of the risk factor although their
levels were increased in both cases.
Significant positive Spearman correlations between
total COPs and total triglycerides (p = 0.012), between
total COPs and systolic and diastolic arterial pressure
(p = 0.038 and p = 0.06, respectively) and between total
COPs and BMI (p = 0.015) were obtained (table V). On
the contrary, as it could have been expected, a negative
and significant Spearman correlation between total
COPs and HDL was found (p = 0.029). No significant
correlations between total COPs and glucose levels
were found. Regarding correlations between serum
cholesterol levels and different CVD, only negative
Spearman significant correlations between cholesterol
and HDL (p < 0.001) were found (table V). 
Discussion
The high variability found for the amount of COPs in
the analyzed subjects serum shows that their level is
probably affected by several factors. The major oxys-
terol detected in this study, 7α-hydroxycholesterol, is
partially formed in vivo by the liver specific cholesterol
Table III
Serum COPs concentrations [μg/mL] regarding hypertension and diabetes
COPs (μg/mL) Total COPs 7α-hydroxy 7β-hydroxy 5,6β-epoxy- 5,6α-epoxy- Cholestanetriol 7-keto-
cholesterol cholesterol cholesterol cholesterol cholesterol
Hypertension
No (n = 42) 0.61 ± 0.41 0.23 ± 0.21 0.20 ± 0.15 0.06 ± 0.05 0.04 ± 0.04 0.03 ± 0.03 0.05 ± 0.04
Yes (n = 45) 0.89 ± 0.59 0.37 ± 0.33 0.29 ± 0.24 0.06 ± 0.05 0.05 ± 0.04 0.04 ± 0.03 0.08 ± 0.06
p * * * n.s. n.s. n.s. *
Diabetes
No (n = 70) 0.70 ± 0.50 0.27 ± 0.27 0.23 ± 0.20 0.06 ± 0.05 0.04 ± 0.04 0.03 ± 0.03 0.06 ± 0.05
Yes (n = 16) 1.00 ± 0.8 0.44 ± 0.32 0.33 ± 0.21 0.06 ± 0.03 0.05 ± 0.03 0.03 ± 0.02 0.09 ± 0.07
p * * * n.s. n.s. n.s. *
Results are expressed as mean ± standard deviations. * p < 0.05; n.s.: non significant.
Table IV
Serum COPs concentrations [μg/mL] regarding obesity (IMC > 30.0 kg/m2) and overweight + obesity (IMC > 25.0 kg/m2)
COPs (μg/mL) Total COPs 7α-hydroxy 7β-hydroxy 5,6β-epoxy- 5,6α-epoxy- Cholestanetriol 7-keto-
cholesterol cholesterol cholesterol cholesterol cholesterol
Obesity
BMI < 29.9 kg/m2 (n = 71) 0.71 ± 0.80 0.28 ± 0.28 0.23 ± 0.18 0.06 ± 0.06 0.04 ± 0.04 0.03 ± 0.03 0.06 ± 0.05
BMI > 30 kg/m2 (n =13) 1.05 ± 0.60 0.44 ± 0.32 0.37 ± 0.27 0.06 ± 0.04 0.05 ± 0.03 0.03 ± 0.03 0.07 ± 0.06
p * P = 0.07 P = 0.08 n.s. n.s. n.s. n.s.
Overweight + Obesity
BMI < 24.9 kg/m2 (n = 26) 0.60 ± 0.40 0.22 ± 0.22 0.20 ± 0.15 0.05 ± 0.04 0.04 ± 0.02 0.03 ± 0.03 0.06 ± 0.05
BMI > 25 kg/m2 (n = 58) 0.84 ± 0.57 0.35 ± 0.31 0.28 ± 0.22 0.06 ± 0.05 0.05 ± 0.04 0.04 ± 0.03 0.07 ± 0.05
p * * P = 0.06 n.s. n.s. n.s. n.s.
Results are expressed as mean ± standard deviations. *p < 0.05; n.s.: non significant.
Fig. 1.—Concentration of Total Cholesterol Oxidation Products
(μg/mL serum) in relation to the absence (1) or presence (2) of
different CVD risk factors in the studied volunteers (n = 88).
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1: Volunteers without risk factors (from the left to the right, the bars represent choles-
terolemia, low HDL, total triglycerides, hypertension, diabetes, obesity and over-
weight+obesity). 
2: Volunteers with risk factors (from the left to the right, the bars represent choles-
terolemia, low HDL, total triglycerides, hypertension, diabetes, obesity and overweight
+ obesity).
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7α-hydroxylase (CYP7A), a P-450 enzyme of liver
microsomes limiting step in the synthesis of primary
bile acids,27 but it is also a common non-enzymatic cho-
lesterol oxidation product that may be formed by sec-
ondary lipid peroxidations.28 7β-hydroxycholesterol is
generally regarded as COPs formed in vivo by a non-
enzymatic mechanism because no specific enzymes
responsible for their formation have yet discovered in
humans.29 25-hydroxycholesterol, the only non-
detected COPs among those analyzed, it is a minor
cholesterol oxidation product in human plasma and in
atherosclerotic lesions,5 Diczfalusy 2009 et al.30 have
described values around 5 ng/ml for this oxysterol. 
Increased plasma cholesterol levels, particularly
LDL, are considered one of the most important risk
factor for CVD by several institutions as the Framing-
ham Heart Study,31 the Multiple Risk Factor Interven-
tion Trial (MRFIT)32 or the Lipid Research Clinics tri-
als.33 Nevertheless, the mechanisms by which
cholesterol contributes to the initiation and progression
of atherosclerotic lesions are not still clear owing to its
lack of reactivity per se.8 Although the concentration of
LDL in circulation is important in determining its
uptake into the endothelium during the development of
atherosclerosis, LDL particles are taken especially
after being oxidized and may be then deposited in the
arterial intima, thus leading to the formation of
atheroma. In a previous paper it was also found that no
correlation exists between serum cholesterol and levels
of serum COPs when analyzing the effects of feeding
on rats with different diets.3 In this sense, the fact that
levels of serum COPs did not show correlations with
hypercholesterolemia, which is in agreement with
other researchers,34,35 has induced to some authors to
hypothesize that COPs could be used as more appropri-
ate markers for the development of atherosclerosis than
cholesterol or LDL in normocholesterolemic patients
with atherosclerosis of the lower limbs.36
In addition, HDL has been proposed to protect
against the development of CDV by facilitating the
transport of cholesterol in periphericall cells back to
the liver for removal from the body (reverse cholesterol
transport). It has been demonstrated that there is an
inverse association between plasma HDL level and
incidence of CVD. Constantly low HDL concentration
in young healthy men free from other coronary risk fac-
tors, is associated with increased in vivo LDL oxidation
and with arterial endothelial vasodilatory dysfunc-
tion.37 HDL was found to protect macrophages from
apoptosis induced by oxidized LDL or by loading with
free cholesterol.38 7-ketocholesterol and related oxys-
terols modified at the C7 position are selectively
exported to HDL by macrophages ATP-binding cas-
sette transporter ABCG1 having a protective role in
advanced atherosclerotic plaques. The negative corre-
lation found between total COPs and HDL cholesterol
pointed out the potential importance of HDL levels in
preventing oxidative mechanisms which occur during
the development of atherosclerosis. However, these
results were not confirmed by the differences observed
for COPs between both groups, high and low HDL
cholesterol, which did not reach statistical signifi-
cance. 
Many studies have shown an association between
high level of plasma triglycerides (TG) and CVD.39 In
contrast, there is a controversial debate whether hyper-
triglycerolemia represents a risk factor independent of
other factors that are often related to it.40 One remark-
able finding of the present work is that total COPs
analysed in this study were significantly higher in
hypertriglycerolemic patients, showing also a positive
and significant correlation between both variables. 
This study also showed that hypertensive patients
showed significantly higher COPs concentrations in
serum than non-hypertensive ones. High blood pres-
sure is a reversible risk factor and even small reduc-
tions in blood pressure can imply large beneficial
effects on the risk of CVD.41 In hypertension, there is an
enhancement of lipid peroxidation and antioxidant
consumption in plasma. Furthermore, COPs inhibit
nitric oxide radical production, considered as the major
endothelium-derived relaxing factor.42 Moriel et al.43
found higher concentrations of 7-ketocholesterol, 5α-
cholestane-3β,5,6β-triol and 5,6α-epoxy-5α-cholestan-
3α-ol in LDL particles of hypertensive patients than in
those of normotensive subjects, despite the normal
concentrations of cholesterol and triglycerides found in
hypertensive patients. Studies in rabbits showed that
induction of hypertension by coarctation of the aorta
gave rise to an enhancement of COPs in plasma and
Table V
Correlation between serum COPs and cholesterol levels and CDV risk factors
CVD risk factor HDL Triglycerides Sistolic Diastolic BMI Glucose
cholesterol blood pressure blood pressure
Correlation with serum COPS
R Spearman -0.236 0.273 0.31 0.291 0.264 0.092
p 0.029 0.012 0.038 0.006 0.015 n.s.
Correlation with serum cholesterol
R Spearman -0.226 0.197 -0.03 0.176 -0.096 -0.288
p 0.037 n.s. n.s. n.s. n.s. 0.011
n.s.: non significant (p > 0.05).
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aortic tissue.44 There were significant differences
between the two groups for total COPs levels, detect-
ing significant increased levels of cholesterol oxides at
C7 position. 
Diabetes is a major independent CVD risk factor.45
The finding that COPs levels were significantly
increased in diabetic patients is relevant because COPs,
in addition to be biomarkers of oxidative stress, also
have cytotoxic and proinflamatory effects, which can
be related to the implications of diabetes.8 Other
authors46,47 also found high concentrations of plasma
oxysterols in patients with diabetes mellitus. Yoshioka
et al.48 studied whether diabetes enhanced lipid peroxi-
dation in diabetic Wistar rats detecting higher levels of
7α-hydroxycholesterol, 7β-hydroxycholesterol and 7-
ketocholesterol in diabetic rats than in control ones. 
Overweight/obesity is a major, modifiable risk fac-
tor for CDV although the link between increased fat
mass and atherosclerosis is still unknown.49 This study
revealed that subjects with BMI > 25 kg/m2 had signifi-
cantly increased serum COPs levels, and even higher
quantitative differences were detected for COPs values
between those subjects suffering obesity (BMI > 30
kg/m2) compared to non obese subjects. Alkazemi et
al.17 also found increased serum COPs concentration
with obesity, detecting increased levels of 7-oxys-
terols. The increases of serum COPs from autoxidation
origin with obesity could be related with data suggest-
ing that oxidative stress is a risk factor for obesity.50,51.
In summary, serum levels of COPs with patophysio-
logic interest are positively related to five CVD risk
factors (hypertriglyceridemia, hypertension, diabetes,
obesity and overweight). It could be interesting to
determine in which extent these oxysterols are origi-
nated in the organism or proceed from the diet. Also the
study of the viability of the use of these compounds as
potential biomarkers of development of CVD would be
of great interest.
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